- Home
- IMCR vs GDYN Comparison
IMCR vs GDYN Comparison
Compare IMCR & GDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- GDYN
- Stock Information
- Founded
- IMCR 2008
- GDYN 2006
- Country
- IMCR United Kingdom
- GDYN United States
- Employees
- IMCR N/A
- GDYN N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- GDYN Computer Software: Prepackaged Software
- Sector
- IMCR Health Care
- GDYN Technology
- Exchange
- IMCR Nasdaq
- GDYN Nasdaq
- Market Cap
- IMCR 1.5B
- GDYN 1.2B
- IPO Year
- IMCR 2021
- GDYN N/A
- Fundamental
- Price
- IMCR $28.40
- GDYN $14.02
- Analyst Decision
- IMCR Buy
- GDYN Strong Buy
- Analyst Count
- IMCR 11
- GDYN 5
- Target Price
- IMCR $59.11
- GDYN $17.60
- AVG Volume (30 Days)
- IMCR 265.8K
- GDYN 600.7K
- Earning Date
- IMCR 05-07-2025
- GDYN 05-01-2025
- Dividend Yield
- IMCR N/A
- GDYN N/A
- EPS Growth
- IMCR N/A
- GDYN 322.00
- EPS
- IMCR N/A
- GDYN 0.13
- Revenue
- IMCR $333,581,000.00
- GDYN $371,169,000.00
- Revenue This Year
- IMCR $20.26
- GDYN $22.34
- Revenue Next Year
- IMCR $8.49
- GDYN $17.88
- P/E Ratio
- IMCR N/A
- GDYN $110.75
- Revenue Growth
- IMCR 25.75
- GDYN 18.72
- 52 Week Low
- IMCR $23.15
- GDYN $9.07
- 52 Week High
- IMCR $62.22
- GDYN $25.50
- Technical
- Relative Strength Index (RSI)
- IMCR 45.68
- GDYN 48.56
- Support Level
- IMCR $27.88
- GDYN $12.97
- Resistance Level
- IMCR $31.38
- GDYN $14.93
- Average True Range (ATR)
- IMCR 1.60
- GDYN 0.64
- MACD
- IMCR -0.08
- GDYN 0.19
- Stochastic Oscillator
- IMCR 22.19
- GDYN 61.94
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.